Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 11, pp 1417–1426 | Cite as

Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites

  • Hye-In Lee
  • Ji-Young Byeon
  • Young-Hoon Kim
  • Choong-Min Lee
  • Chang-Ik Choi
  • Choon-Gon Jang
  • Jung-Woo Bae
  • Yun Jeong Lee
  • Seok-Yong Lee
Pharmacogenetics
  • 154 Downloads

Abstract

Purpose

CYP3A4, CYP2C19, and CYP3A5 are primarily involved in the metabolism of cilostazol. We investigated the effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its two active metabolites.

Methods

Thirty-three healthy Korean volunteers were administered a single 100-mg oral dose of cilostazol. The concentrations of cilostazol and its active metabolites (OPC-13015 and OPC-13213) in the plasma were determined by HPLC-MS/MS.

Results

Although the pharmacokinetic parameters for cilostazol were similar in different CYP2C19 and CYP3A5 genotypes, CYP2C19PM subjects showed significantly higher AUC0-∞ for OPC-13015 and lower for OPC-13213 compared to those in CYP2C19EM subjects (P < 0.01 and P < 0.001, respectively). Pharmacokinetic differences in OPC-13015 between CYP3A5 non-expressors and expressors were significant only within CYP2C19PM subjects. The amount of cilostazol potency-adjusted total active moiety was the greatest in subjects with CYP2C19PM-CYP3A5 non-expressor genotype.

Conclusion

These results suggest that CYP2C19 and CYP3A5 genetic polymorphisms affect the plasma exposure of cilostazol total active moiety. CYP2C19 plays a crucial role in the biotransformation of cilostazol.

Keywords

Cilostazol CYP2C19 CYP3A5 Genetic polymorphism Pharmacokinetics 

Notes

Funding information

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (NRF-2016R1A2B4007381).

Compliance with ethical standards

All subjects provided verbal and written informed consent. This study was performed in accordance with the guidelines of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of Sungkyunkwan University, Suwon, Korea.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2018_2522_MOESM1_ESM.pptx (5.6 mb)
ESM 1 (PPTX 5696 kb)

References

  1. 1.
    Kimura Y, Tani T, Kanbe T et al (1985) Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144–1149PubMedGoogle Scholar
  2. 2.
    Uchikawa T, Murakami T, Furukawa H (1992) Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung 42:322–324PubMedGoogle Scholar
  3. 3.
    Dawson DL, Cutler BS, Meissner MH et al (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678–686CrossRefGoogle Scholar
  4. 4.
    Pletal [label]. Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan, 2007 < http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020863s021lbl.pdf>
  5. 5.
    Bramer SL, Forbes WP (1999) Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. Clin Pharmacokinet 37:25–32CrossRefGoogle Scholar
  6. 6.
    Ishida S, Morii M, Ueno K et al (2000) Studies on factor affecting pharmacokinetics of cilostazol and pharmacokinetics-pharmacodynamics analysis based platelet aggregation. Jpn J Hosp Pharm 26:264–272CrossRefGoogle Scholar
  7. 7.
    Suri A, Bramer SL (1999) Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 37:53–59CrossRefGoogle Scholar
  8. 8.
    Okuda Y, Kimura Y, Yamashita K (1993) Cilostazol. Cardiovasc Drug Rev 11:451–465CrossRefGoogle Scholar
  9. 9.
    Akiyama H, Kudo S, Shimizu T (1985) The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. Arzneimittelforschung 35:1133–1140PubMedGoogle Scholar
  10. 10.
    Abbas R, Chow CP, Browder NJ et al (2000) In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum Exp Toxicol 19:178–184CrossRefGoogle Scholar
  11. 11.
    Hiratsuka M, Hinai Y, Sasaki T et al (2007) Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 35:1730–1732CrossRefGoogle Scholar
  12. 12.
    Yoo HD, Park SA, Cho HY et al (2009) Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. Clin Pharmacol Ther 86:281–284CrossRefGoogle Scholar
  13. 13.
    Yoo HD, Cho HY, Lee YB (2010) Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 69:27–37CrossRefGoogle Scholar
  14. 14.
    Kim HS, Lim Y, Oh M et al (2016) The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Br J Clin Pharmacol 81:301–312CrossRefGoogle Scholar
  15. 15.
    Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295CrossRefGoogle Scholar
  16. 16.
    de Morais SM, Wilkinson GR, Blaisdell J et al (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422PubMedGoogle Scholar
  17. 17.
    de Morais SM, Wilkinson GR, Blaisdell J et al (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598PubMedGoogle Scholar
  18. 18.
    Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113CrossRefGoogle Scholar
  19. 19.
    Li-Wan-Po A, Girard T, Farndon P et al (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69:222–230CrossRefGoogle Scholar
  20. 20.
    Desta Z, Zhao X, Shin JG et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958CrossRefGoogle Scholar
  21. 21.
    Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192–209CrossRefGoogle Scholar
  22. 22.
    Zhang YA, Reviriego J, Lou YQ et al (1990) Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 48:496–502CrossRefGoogle Scholar
  23. 23.
    van Schaik RH, van der Heiden IP, van den Anker JN et al (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668–1671PubMedGoogle Scholar
  24. 24.
    Yu KS, Cho JY, Jang IJ et al (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104–112CrossRefGoogle Scholar
  25. 25.
    Hu YF, He J, Chen GL et al (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353:187–192CrossRefGoogle Scholar
  26. 26.
    Kuehl P, Zhang J, Lin Y et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391CrossRefGoogle Scholar
  27. 27.
    Lee SJ, Usmani KA, Chanas B et al (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461–472CrossRefGoogle Scholar
  28. 28.
    Givens RC, Lin YS, Dowling AL et al (2003) CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 95:1297–1300CrossRefGoogle Scholar
  29. 29.
    Dai Y, Hebert MF, Isoherranen N et al (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–847CrossRefGoogle Scholar
  30. 30.
    Zheng H, Webber S, Zeevi A et al (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477–483CrossRefGoogle Scholar
  31. 31.
    Wong M, Balleine RL, Collins M et al (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75:529–538CrossRefGoogle Scholar
  32. 32.
    Park JY, Kim KA, Park PW et al (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79:590–599CrossRefGoogle Scholar
  33. 33.
    Ferraresso M, Tirelli A, Ghio L et al (2007) Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 11:296–300CrossRefGoogle Scholar
  34. 34.
    Lamba JK, Lin YS, Thummel K et al (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121–132CrossRefGoogle Scholar
  35. 35.
    Fukushima-Uesaka H, Saito Y, Watanabe H et al (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100.  https://doi.org/10.1002/humu.9210 CrossRefPubMedGoogle Scholar
  36. 36.
    Yamamoto T, Nagafuchi N, Ozeki T et al (2003) CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 18:267–268CrossRefGoogle Scholar
  37. 37.
    Hu YF, He J, Chen GL et al (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353:187–192CrossRefGoogle Scholar
  38. 38.
    Du J, Xing Q, Xu L et al (2006) Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7:831–841CrossRefGoogle Scholar
  39. 39.
    Lee SJ, Lee SS, Jeong HE et al (2007) The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 35:2095–2101CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of PharmacySungkyunkwan UniversitySuwonRepublic of Korea
  2. 2.College of PharmacyDongguk University-SeoulGoyangRepublic of Korea
  3. 3.College of PharmacyKeimyung UniversityDaeguRepublic of Korea
  4. 4.College of PharmacyDankook UniversityCheonanRepublic of Korea

Personalised recommendations